Treatment with biologic therapies and the risk of cancer in patients with IBD. (Q36724676)

15 August 2017

1 reference

title

Treatment with biologic therapies and the risk of cancer in patients with IBD. (English)

1 reference

15 August 2017

Livia Biancone

1

1 reference

15 August 2017

Emma Calabrese

series ordinal

2

1 reference

15 August 2017

Carmelina Petruzziello

series ordinal

3

1 reference

15 August 2017

Francesco Pallone

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Nature Reviews Gastroenterology & Hepatology

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

78-91

1 reference

Inflammatory bowel disease: etiology and pathogenesis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Immunity, inflammation, and allergy in the gut.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Crohn's disease: step up or top down therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Intestinal cancer risk and mortality in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Crohn's disease and cancer: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

The relationship between infliximab treatment and lymphoma in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Acute leukemia after infliximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Epstein-Barr virus-associated lymphoma in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Biologics in inflammatory disease: infliximab associated risk of lymphoma development

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Eruptive tufted angiomas in a patient with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Carcinoma arising in enterocutan fistulae of Crohn's disease patients: description of two cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Case records of the Massachusetts General Hospital. Case 8-2006. A 71-year-old woman with Crohn's disease and altered mental status

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Inflammatory bowel disease is not associated with an increased risk of lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Risks and benefits of infliximab for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab for patients with refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab for treatment of steroid-refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A pilot study of adalimumab in infliximab-allergic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0695

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0695

1 reference

Dimensions Publication ID

15 August 2017

1041634111

0 references

1 reference